ImmunoPrecise Antibodies Ltd. (IPA)
Chart Events
Performance Outlook
| Previous Close | 6.33 |
| Open | 6.13 |
| Bid | 6.01 x 900 |
| Ask | 6.22 x 2200 |
| Day's Range | 6.05 - 6.13 |
| 52 Week Range | 3.51 - 8.10 |
| Volume | |
| Avg. Volume | 16,320 |
| Market Cap | 150.601M |
| Beta (5Y Monthly) | 0.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.69 |
| Earnings Date | Sep 07, 2022 - Sep 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.87 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IPA
Related Research
- ImmunoPrecise Antibodies Ltd.Analyst Report: APA CorporationBased in Houston, APA Corp. is an independent exploration and production company. It operates primarily in the U.S., Egypt, the North Sea, and Suriname. At year-end 2021, proved reserves totaled 913 million barrels of oil equivalent, with net reported production of 388 mboe/d (64% of which was oil and natural gas liquids, with the remainder comprising natural gas).RatingFair ValueEconomic Moat15 hours agoMorningstar
- Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
VICTORIA, British Columbia, July 29, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for the full fiscal year 2022 ended April 30, 2022.
- Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
VICTORIA, British Columbia, July 26, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.
- Business Wire
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
VICTORIA, British Columbia, July 12, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, reports the critical third-party findings of two IND-enabling pre-clinical safety studies, de-risking the clinical development of the Company’s PolyTope® TATX-03 antibody cocktail and its potential to prevent and treat COVID-19. A summary of the positive findings indicates that, through ex vivo screenings, n
